Jade Biosciences, Inc.
JBIO · XNASCIK 1798749fmd_0S110RBGB87BPXGF3YT1TC2WNDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 8 | 15 | 39 | 64 | 53 | 93 |
| Total operating expenses | 9 | 23 | 53 | 81 | 75 | 114 |
| Compensation and benefits | – | – | – | 21 | 20 | – |
| Operating income | (9) | (23) | (53) | (81) | (75) | (114) |
| Interest expense | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 0 | 2 | 6 | 5 | (14) |
| Income before taxes | (10) | (23) | (51) | (75) | (70) | (127) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (23) | (52) | (76) | (70) | (127) |
| Net income | (10) | (23) | (52) | (76) | (70) | (127) |
| Net income to common shareholders | (10) | (23) | (52) | (76) | (70) | (100) |